-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, C1Oy6QUwt9cYjNqqt3z1XDl7VLUa6B0NkeL6AckQ3yFKQw1/hlHhC7K75fg4xdya UN4/u/4t8NyRdPXDi7Jx9w== 0001013762-08-001133.txt : 20080516 0001013762-08-001133.hdr.sgml : 20080516 20080515191315 ACCESSION NUMBER: 0001013762-08-001133 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080515 ITEM INFORMATION: Other Events FILED AS OF DATE: 20080516 DATE AS OF CHANGE: 20080515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMAZON BIOTECH INC CENTRAL INDEX KEY: 0001088781 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870416131 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26753 FILM NUMBER: 08840018 BUSINESS ADDRESS: STREET 1: 43 WEST 33RD STREET STREET 2: SUITE 405 CITY: NEW YORK STATE: NY ZIP: 84107 BUSINESS PHONE: (212) 695-3003 MAIL ADDRESS: STREET 1: 43 WEST 33RD STREET STREET 2: SUITE 405 CITY: NEW YORK STATE: NY ZIP: 84107 FORMER COMPANY: FORMER CONFORMED NAME: ASYST CORP DATE OF NAME CHANGE: 19990615 8-K 1 form8k.htm AMAZON BIOTECH, INC. FORM 8-K Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest reported): May 15, 2008

(Exact name of registrant as specified in charter)

Utah
000-26753
87-0416131
(State  or  Other  Jurisdiction of Incorporation or Organization)
(Commission File Number)
(IRS Employer Identification No.)

43 West 33rd Street
New York, New York 10001
 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (212) 695-3334

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
 
 
Other Events.

 
As previously announced, on May 4, 2008, shareholders holding a majority of the outstanding shares of common stock of Amazon Biotech, Inc. (the “Company”) terminated Simcha Edell and Mechael Kanovsky as directors of the Company (the “Terminated Directors”).  The Terminated Directors had previously submitted resignation as executive officers of the Company.  Eliyahu BenTal Tolchinsky was appointed by the majority shareholders as director of the Company and was appointed as the Chief Executive Officer and President of the Company.   On May 14, 2008, Mr. Kanovsky, the former Chief Executive Officer, filed a Form 8K with the Securities and Exchange Commission challenging the validity of the removal of the Terminated Directors and the resignation of the executive officers.  The filing of this Form 8K by Mr. Kanovsky was not valid and was not authorized by the management of the Company.
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  AMAZON BIOTECH, INC.  
       
Date: May 15, 2008 
By:
/s/ Eliyahu BenTal Tolchinsky  
    Name: Eliyahu Bental Tolchinsky  
   
Title: CEO
  
       

 
 
 -----END PRIVACY-ENHANCED MESSAGE-----